Navigation Links
Beardsworth Continues to Strengthen Oncology Operations
Date:5/4/2011

FLEMINGTON, N.J., May 4, 2011 /PRNewswire/ -- Beardsworth announces the promotion of Evette Riegel, RN, to Senior Director, Clinical Operations and Project Management and the addition of Saishree Ramalingam, MS, MPhil as Senior Project Manager.  

(Photo:  http://photos.prnewswire.com/prnh/20110504/NY95605 )

In her new role, Ms. Riegel will lead Beardsworth's expanded focus in oncology clinical operations and execution of all clinical programs.

"Evette's expertise and insight provide an added dimension that strengthens our client services and capabilities across our global OncologyOne(SM) and therapeutic vaccine initiatives.  Her global trial experience and extensive therapeutic knowledge combined with her personal insight as a critical care nurse, give her a unique perspective from which to lead our patient-centric, project management teams," said Michael O'Brien, President & CEO.

Ms. Riegel joined Beardsworth in 2006 as a Senior Project Manager and became Director, Clinical Operations in 2008 with a leading role in the integration of Beardsworth's global services and oncology operations. Previously, Ms. Riegel worked at Quintiles as a global project manager as well as Discovery Laboratories, ViroPharma, and Wyeth.

Saishree Ramalingam, MS, MPhil joins Beardsworth as a Senior Project Manager responsible for leading the company's oncology trials. An experienced research clinician, Ms. Ramalingam has over 13 years experience across multiple therapeutic areas and global projects with a special focus in oncology and vaccines.

Prior to Beardsworth, Ms. Ramalingam held project manager positions at Celgene, Pfizer, GSK/Reliant, Merck, as well as PharmaNet, Applied Clinical Intelligence, and PRA International. She received her master of science at the University of Akron and a master of philosophy from Avinashilingam Deemed University, Coimbatore, India.

"We are thrilled to have Saishree on the Beardsworth team," said Evette Riegel. "The depth and scope of her expertise, global project experience, and strong cross-functional leadership capabilities are immediate assets to our clients, our partners, and our project teams."

Headquartered in Flemington, New Jersey, Beardsworth is a full-service CRO specializing in business solutions for complex clinical trials focused on oncology and therapeutic vaccine. Our multi-disciplined staff averages 20+ years experience supporting research studies from trial design through clinical project management to FDA approval. Beardsworth is the founding partner of OncologyOne(SM) – an alliance of best-in-class regional CROs providing full-service strategies for global oncology trials. Celebrating its 25th year, Beardsworth is a CCR registrant and Certified Small Business.

www.beardsworth.com


'/>"/>
SOURCE Beardsworth
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Alison Martin, MD and Robert W. Malone, MD Join Beardsworth
2. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
5. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
6. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
9. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
10. ACORN CRO Continues Growth in Strong Third Quarter
11. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company ... National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month ... technology and is expected to deliver therapeutic levels of olanzapine for a period of ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
Breaking Biology Technology:
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):